Brief: Basilea Pharmaceutica: 2026 Financial Guidance 10% Increase In Total Revenue Driving 20% Increase In Operating Profit

Basilea Pharmaceutica AG, Allschwil

17/02/2026 06:19

Feb 17 (Reuters) - BASILEA PHARMACEUTICA AG ALLSCHWIL BSLN.S:

FY OPERATING INCOME CHF 51.5 MILLION

FY NET INCOME CHF 40.2 MILLION

FY PRETAX PROFIT CHF 45.9 MILLION

FY BASIC EPS CHF 3.29

FY EPS CHF 3.14

FY OPERATING EXPENSES CHF -180.8 MILLION

GUIDANCE FY 2026: DOUBLE-DIGIT INCREASE IN TOTAL REVENUE AND OPERATING PROFIT

2026 FINANCIAL GUIDANCE: 10% INCREASE IN TOTAL REVENUE DRIVING 20% INCREASE IN OPERATING PROFIT

OVER NEXT FIVE YEARS, BASILEA EXPECTS TO ADD CHF 600 MILLION IN CUMULATIVE CASH FLOWS FROM CRESEMBA AND ZEVTERA

THERE IS APPROXIMATELY USD 330 MILLION OF POTENTIAL ADDITIONAL NON-DILUTIVE RESEARCH AND DEVELOPMENT FUNDING AWARDED UNDER BASILEA'S EXISTING AGREEMENTS WITH BARDA

Source text: ID:nGNE7Jj3gg

Further company coverage: BSLN.S

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))